TR200501137T2 - Endothelin antagonists. - Google Patents
Endothelin antagonists.Info
- Publication number
- TR200501137T2 TR200501137T2 TR2005/01137T TR200501137T TR200501137T2 TR 200501137 T2 TR200501137 T2 TR 200501137T2 TR 2005/01137 T TR2005/01137 T TR 2005/01137T TR 200501137 T TR200501137 T TR 200501137T TR 200501137 T2 TR200501137 T2 TR 200501137T2
- Authority
- TR
- Turkey
- Prior art keywords
- endothelin antagonists
- disclosed
- endothelin
- prepare
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Bir formül (I) bileşiği veya farmasötik olarak kabul edilebilir bir tuzu açıklanmaktadır; ayrıca bunları hazırlamak için işlemler ve bunları hazırlamak için kullanılan ara maddelerin yanı sıra endotelini antagonize etmek için bir yöntem açıklanmaktadır.A compound of formula (I) or a pharmaceutically acceptable salt thereof is disclosed; also disclosed processes for their preparation and a method for antagonizing endothelin as well as intermediates used to prepare them.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/905,913 US6162927A (en) | 1994-08-19 | 1997-08-04 | Endothelin antagonists |
US4895598A | 1998-03-27 | 1998-03-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200501137T2 true TR200501137T2 (en) | 2005-12-21 |
Family
ID=26726720
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01233T TR200101233T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
TR2001/01234T TR200101234T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
TR2005/01137T TR200501137T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
TR2000/00993T TR200000993T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/01233T TR200101233T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
TR2001/01234T TR200101234T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2000/00993T TR200000993T2 (en) | 1997-08-04 | 1998-07-27 | Endothelin antagonists. |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1003740A2 (en) |
JP (1) | JP2001512119A (en) |
CN (1) | CN1301264A (en) |
AU (1) | AU748469B2 (en) |
BG (1) | BG104216A (en) |
BR (1) | BR9815296A (en) |
CA (1) | CA2297894A1 (en) |
HU (1) | HUP0003484A3 (en) |
IL (1) | IL134175A0 (en) |
NO (1) | NO20000542L (en) |
NZ (1) | NZ502395A (en) |
PL (1) | PL342500A1 (en) |
SK (1) | SK1452000A3 (en) |
TR (4) | TR200101233T2 (en) |
TW (1) | TW552260B (en) |
WO (1) | WO1999006397A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1097236A4 (en) * | 1998-07-15 | 2006-10-04 | Bristol Myers Squibb Co | Stereoselective reductive amination of ketones |
TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
EP1354882A1 (en) * | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
BR0205970A (en) * | 2001-04-11 | 2003-09-30 | Abbott Lab | Favorable modulation of health-related quality of life and time-adjusted quality of progression of health-related disease in prostate cancer patients |
FR2874015B1 (en) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2007034406A1 (en) * | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
US20090054473A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
JO2998B1 (en) | 2010-06-04 | 2016-09-05 | Amgen Inc | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
WO2013049250A1 (en) | 2011-09-27 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
JOP20200296A1 (en) | 2013-06-10 | 2017-06-16 | Amgen Inc | Processes of Making and Crystalline Forms of a MDM2 Inhibitor |
CN104262329A (en) * | 2014-10-22 | 2015-01-07 | 南京友杰医药科技有限公司 | Preparation method for anti-form atrasentan |
WO2024022262A1 (en) * | 2022-07-25 | 2024-02-01 | 深圳信立泰药业股份有限公司 | Salt of endothelin a (eta) receptor antagonist compound, and preparation method therefor and medical use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013842A (en) * | 1990-01-22 | 1991-05-07 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
DE69527072T2 (en) * | 1994-08-19 | 2003-02-13 | Abbott Lab | ENDOTHELIN ANTAGONISTE |
DE69714024T2 (en) * | 1996-02-13 | 2003-03-20 | Abbott Lab | 4- (BENZO-1,3-DIOXOLYL) -PYRROLIDIN-3-CARBONIC ACID DERIVATIVES AS ENDOTHELINE ANTAGONISTS |
US5618949A (en) * | 1996-07-12 | 1997-04-08 | Abbott Laboratories | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds |
-
1998
- 1998-07-27 CN CN98809462A patent/CN1301264A/en active Pending
- 1998-07-27 SK SK145-2000A patent/SK1452000A3/en unknown
- 1998-07-27 TR TR2001/01233T patent/TR200101233T2/en unknown
- 1998-07-27 WO PCT/US1998/015479 patent/WO1999006397A2/en not_active Application Discontinuation
- 1998-07-27 IL IL13417598A patent/IL134175A0/en unknown
- 1998-07-27 PL PL98342500A patent/PL342500A1/en not_active Application Discontinuation
- 1998-07-27 TR TR2001/01234T patent/TR200101234T2/en unknown
- 1998-07-27 HU HU0003484A patent/HUP0003484A3/en unknown
- 1998-07-27 AU AU85921/98A patent/AU748469B2/en not_active Ceased
- 1998-07-27 BR BR9815296-3A patent/BR9815296A/en not_active Application Discontinuation
- 1998-07-27 TR TR2005/01137T patent/TR200501137T2/en unknown
- 1998-07-27 EP EP98937139A patent/EP1003740A2/en not_active Ceased
- 1998-07-27 JP JP2000505155A patent/JP2001512119A/en active Pending
- 1998-07-27 TR TR2000/00993T patent/TR200000993T2/en unknown
- 1998-07-27 NZ NZ502395A patent/NZ502395A/en unknown
- 1998-07-27 CA CA002297894A patent/CA2297894A1/en not_active Abandoned
- 1998-08-10 TW TW087112783A patent/TW552260B/en not_active IP Right Cessation
-
2000
- 2000-02-02 NO NO20000542A patent/NO20000542L/en not_active Application Discontinuation
- 2000-03-02 BG BG104216A patent/BG104216A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SK1452000A3 (en) | 2001-05-10 |
PL342500A1 (en) | 2001-06-04 |
TR200000993T2 (en) | 2000-12-21 |
JP2001512119A (en) | 2001-08-21 |
TR200101233T2 (en) | 2002-06-21 |
TW552260B (en) | 2003-09-11 |
HUP0003484A3 (en) | 2002-02-28 |
TR200101234T2 (en) | 2002-06-21 |
EP1003740A2 (en) | 2000-05-31 |
AU8592198A (en) | 1999-02-22 |
WO1999006397A3 (en) | 1999-12-09 |
BG104216A (en) | 2000-12-29 |
NO20000542L (en) | 2000-04-04 |
BR9815296A (en) | 2001-11-20 |
NZ502395A (en) | 2002-08-28 |
WO1999006397A2 (en) | 1999-02-11 |
CN1301264A (en) | 2001-06-27 |
NO20000542D0 (en) | 2000-02-02 |
IL134175A0 (en) | 2001-04-30 |
AU748469B2 (en) | 2002-06-06 |
CA2297894A1 (en) | 1999-02-11 |
HUP0003484A2 (en) | 2002-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200501137T2 (en) | Endothelin antagonists. | |
DE69831868D1 (en) | Antithrombosemittel | |
DE69830504D1 (en) | ANTITROMOMBOTIC MEANS | |
DE69931393D1 (en) | ANTITHROMBOTIC AMIDE | |
ATE219077T1 (en) | ENDOTHELIN ANTAGONIST | |
PT894084E (en) | CINAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRINE ANTAGONISTS | |
DK0923554T3 (en) | N-Benzylpiperidine and tetrahydropyridine derivatives | |
EP0249224A3 (en) | Novel antihypertensive agent | |
CA2245587A1 (en) | Novel benzo-1,3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists | |
ES8702403A1 (en) | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines. | |
EP1019047A4 (en) | Antithrombotic agents | |
EP0342665A3 (en) | Physiologically active substance tan-931, its derivatives, their production and use | |
NO996244L (en) | Pyrrolidinecarboxylic acid derivatives as endothelin antagonists | |
AU7470098A (en) | Antithrombotic agents | |
AU554257B2 (en) | 6 - methyl - 1,4 dihydropyridine derivatives | |
AU4478489A (en) | Intermediates for the preparation of penem derivatives | |
MX9701220A (en) | Endothelin antagonists. | |
ATE149836T1 (en) | ANTI-PLASMIN DEPRESSANT | |
TR200001161A2 (en) | The process by which 8-Cyclopentyl-6-ethyl-3- [substituted] -5, 8-Dihydro-4H-1, 2, 3A, 7, 8-Pentaaza-As-Indasenes are prepared and useful intermediates therein. | |
DE69824410D1 (en) | Antithrombosemittel |